Selective inhibition of JAK2/STAT1 signaling and iNOS expression mediates the anti-inflammatory effects of coniferyl aldehyde

被引:32
|
作者
Akram, Muhammad [1 ]
Kim, Kyeong-A [1 ]
Kim, Eun-Sun [1 ]
Shin, Young-Jun [1 ]
Noh, Dabi [1 ]
Kim, Eunji [1 ]
Kim, Jeong-Hyeon [1 ]
Majid, Arshad [2 ]
Chang, Sun-Young [3 ]
Kim, Jin-Ki [1 ]
Bae, Ok-Nam [1 ]
机构
[1] Hanyang Univ, Coll Pharm, Inst Pharmaceut Sci & Technol, Ansan, South Korea
[2] Univ Sheffield, Sheffield Inst Translat Neurosci, Sheffield, S Yorkshire, England
[3] Ajou Univ, Coll Pharm, Suwon, South Korea
关键词
Coniferyl aldehyde; Anti-inflammatory activity; JAK2-STAT1; Nitric oxide; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; ISCHEMIC BRAIN-INJURY; FERULIC ACID; RHEUMATOID-ARTHRITIS; ANTIOXIDANT ACTIVITY; SALVIA-PLEBEIA; RAW264.7; CELLS; GROWTH-FACTOR; ACTIVATION;
D O I
10.1016/j.cbi.2016.06.029
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Urgent needs still exist for selective control of excessive inflammation. Despite the therapeutic potential of natural compounds against inflammation-associated chronic conditions, lack of specific molecular targets renders these bioactive compounds difficult for further development. Here we examined the bioactivity of coniferyl aldehyde (CA), a natural phenolic compound found in several dietary substances and medicinal plants, elucidating its efficacy both in vivo and in vitro with underlying molecular mechanisms. IFN-gamma/TNF-alpha-stimulated human keratinocytes and lipopolysaccharide (LPS)-stimulated murine macrophages were used to examine the effect of CA in vitro and to elucidate the underlying mechanisms. In vivo models of phorbol 12-myristate 13-acetate (TPA)-induced ear edema and carrageenan (CRG)-induced paw edema were employed to investigate the topical and systemic anti-inflammatory effects of CA, respectively. CA significantly reduced nitric oxide (NO) production and inducible nitric oxide synthase (iNOS) expression in LPS-stimulated macrophages. While nuclear factor kappa B (NF-kappa B) and mitogen-activated protein kinase (MAPKs) pathways, the representative cellular pathways for iNOS induction, were not affected by CA, phosphorylation of Janus kinase 2 (JAK2) and signal Transducers and Activators of Transcription 1 (STAT1) and subsequent nuclear translocation of p-STAT1 were significantly decreased by CA. The effect of CA on JAK2-STAT1-iNOS axis was also observed in human keratinocytes stimulated with IFN-gamma/TNF-alpha. Topical application of CA to mice produced significant protection against TPA-induced ear edema along with suppressed epidermal hyperproliferation and leucocyte infiltration. Systemic administration of CA significantly reduced CRG-induced paw edema in rats, where CRG-induced iNOS expression and STAT1 phosphorylation were decreased by CA. In summary, CA has significant anti-inflammatory properties both in vitro and in vivo, mediated by significant selective inhibition of JAK2-STAT1-iNOS signaling. CA is an attractive novel candidate for treating inflammatory diseases associated with excessive production of NO. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:102 / 110
页数:9
相关论文
共 50 条
  • [21] Multitarget Antileukemic Effects of Metformin in Myeloproliferative Neoplasm Cells: Inhibition of JAK2/STAT Signaling and Mitochondrial Activity
    Machado-Neto, Joao Agostinho
    Fenerich, Bruna Alves
    Scopim-Ribeiro, Renata
    Dechandt, Carlos Roberto Porto
    Alves, Ana Paula Nunes Rodrigues
    Fernandes, Jaqueline Cristina
    Scheucher, Priscila Santos
    Simoes, Belinda Pinto
    Alberici, Luciane Carla
    Pontes, Lorena Lobo de Figueiredo
    Rego, Eduardo Magalhaes
    Traina, Fabiola
    BLOOD, 2016, 128 (22)
  • [22] Geniposide protects depression through BTK/JAK2/STAT1 signaling pathway in lipopolysaccharide-induced depressive mice
    Zheng, Menglin
    Li, Ke
    Chen, Tong
    Liu, Shengnan
    He, Ling
    BRAIN RESEARCH BULLETIN, 2021, 170 : 65 - 73
  • [23] The anti-inflammatory agent parthenolide has differential and independent effects on Jak-STAT and ERK signaling in cardiac myocytes
    Day, JN
    Booz, GW
    HYPERTENSION, 2004, 44 (04) : 517 - 517
  • [24] Protocatechuic aldehyde protects against isoproterenol-induced cardiac hypertrophy via inhibition of the JAK2/STAT3 signaling pathway
    Fang, Xiuli
    Liu, Yajun
    Lu, Jing
    Hong, Huiqi
    Yuan, Jing
    Zhang, Yuhong
    Wang, Panxia
    Liu, Peiqing
    Ye, Jiantao
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2018, 391 (12) : 1373 - 1385
  • [25] Protocatechuic aldehyde protects against isoproterenol-induced cardiac hypertrophy via inhibition of the JAK2/STAT3 signaling pathway
    Xiuli Fang
    Yajun Liu
    Jing Lu
    Huiqi Hong
    Jing Yuan
    Yuhong Zhang
    Panxia Wang
    Peiqing Liu
    Jiantao Ye
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391 : 1373 - 1385
  • [26] Revisiting bupropion anti-inflammatory action: involvement of the TLR2/TLR4 and JAK2/STAT3
    Karimollah, Alireza
    Hemmatpur, Anahid
    Vahid, Taha
    INFLAMMOPHARMACOLOGY, 2021, 29 (04) : 1101 - 1109
  • [27] Effect of Jak2 kinase inhibition on Stat1 and Stat3 activation and apoptosis of tubular epithelial cells induced by ATP depletion/recovery
    Wang, Jianzhong
    Ouyang, Chun
    Chen, Xiangmei
    Fu, Bo
    Lu, Yang
    Hong, Quan
    JOURNAL OF NEPHROLOGY, 2008, 21 (06) : 919 - 923
  • [28] Revisiting bupropion anti-inflammatory action: involvement of the TLR2/TLR4 and JAK2/STAT3
    Alireza Karimollah
    Anahid Hemmatpur
    Taha Vahid
    Inflammopharmacology, 2021, 29 : 1101 - 1109
  • [29] Lipocalin2 mediates anti-inflammatory functions through the inhibition of STAT3 and activation of STAT5 signaling in bone marrow derived macrophages
    Samuels, Janaiya
    Rayalam, Srujana
    Shashidharamurthy, Rangaiah
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [30] Protective and anti-inflammatory role of REG1A in inflammatory bowel disease induced by JAK/STAT3 signaling axis
    Mao, Hongli
    Jia, Jinlin
    Sheng, Jinxiu
    Zhang, Shanfeng
    Huang, Kaida
    Li, Hongle
    He, Fucheng
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 92